Journal article
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook
Journal of oncology pharmacy practice, Vol.25(6), pp.1486-1490
09/2019
DOI: 10.1177/1078155218788717
PMID: 30045683
Abstract
Ibrutinib has revolutionized the treatment of B-cell malignancies since its approval for chronic lymphocytic leukemia. It is also used in mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstrom's macroglobulinemia, among others. It is a Bruton's tyrosine kinase inhibitor that acts on B-cell receptor signaling pathway and predisposes to various infections due to its effects on neutrophils, monocytes and T cells. We present a case of cerebral invasive aspergillosis in a patient being treated with ibrutinib for relapsed chronic lymphocytic leukemia. It was hard to associate the condition to ibrutinib versus the chronic lymphocytic leukemia. The patient was successfully treated with a combination of voriconazole and micafungin, resulting in complete recovery and no residual deficits. This highlights the importance of recognizing the rare complication in those on ibrutinib and initiating the treatment immediately with appropriate antifungal agents to improve prognosis of this potentially fatal condition.
Details
- Title: Subtitle
- Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook
- Creators
- Muhammad Salman Faisal - Allegheny Health NetworkHira Shaikh - Allegheny Health NetworkAhmed Khattab - Allegheny Health NetworkMary Albrethsen - Allegheny Health NetworkSalman Fazal - Allegheny Health Network
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.25(6), pp.1486-1490
- DOI
- 10.1177/1078155218788717
- PMID
- 30045683
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 09/2019
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984695677402771
Metrics
6 Record Views